Vanguard Global Advisers’s Biogen BIIB Stock Holding History

Vanguard Global Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.6M	Sell	335,936 -7,832	-2%	-$1.5M	0.03%	338
2026 Q1	$63M	Buy	+343,768	New	+$63.3M	0.03%	354

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Global Advisers's BIIB Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Biogen (BIIB) stake by 2.3% in Q2 2026, selling an estimated $1.5M and leaving 335,936 shares worth $72.6M. The position accounts for 0.03% of the portfolio, ranked #338.

Vanguard Global Advisers first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Vanguard Global Advisers held 335,936 shares of Biogen worth $72.6M as of Q2 2026.
Vanguard Global Advisers sold 7,832 Biogen shares in Q2 2026, an estimated $1.5M.
Biogen made up 0.03% of Vanguard Global Advisers's portfolio in Q2 2026, its #338 holding.
Vanguard Global Advisers first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.